Skip to main content

Table 7 Acute adverse events recorded during concurrent high-dose intensity-modulated radiation therapy and docetaxel-based chemotherapy: genitourinary symptoms

From: Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial

 

Grade

Frequency/urgency

Dysuria

Incontinence

Retention

Hematuria

Highest

B

A

A*

B

A

A*

B

A

A*

B

A

A*

B

A

A*

A

A*

Cohort 1

1

3

6

3

1

2

1

3

4

1

0

2

2

0

1

1

9

5

2

1

3

2

0

0

0

3

4

1

0

0

0

0

0

0

7

3

3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Cohort 2

1

3

7

4

2

2

1

0

2

2

3

5

2

0

2

2

8

6

2

3

5

2

0

1

1

0

1

1

2

3

1

0

1

1

8

4

 

3

0

0

0

0

0

0

0

0

0

0

1

1

0

0

0

1

1

  1. B = baseline (before concurrent intensity-modulated radiation therapy and docetaxel-based chemotherapy); A = all acute adverse events; A* = acute adverse events of higher grade than baseline.